A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma (KEYNOTE- 942)

This study is testing a new, personalized cancer vaccine combined with an immunotherapy drug to see if it can better prevent high-risk melanoma from coming back after surgery. By training your immune system to specifically recognize your own cancer cells, researchers hope to provide a more effective way to stay cancer-free.

This trial is for people who have recently had high-risk skin cancer completely removed by surgery and have no signs of cancer left in their body. Participants must also be in relatively good physical health and have a sample of their tumor available for lab testing.

Participants will be randomly assigned to receive either the standard immunotherapy drug alone or a combination of that drug and the experimental vaccine. You will be closely monitored by a medical team to see how your body responds to the treatment and to keep track of your health over time.

The study currently has active locations in Tucson, Arizona, and in San Francisco and Santa Monica, California. While the study is currently active, it is not accepting new participants at this time.